Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 45 of 107 for:    "21-hydroxylase deficiency"

An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03019614
Recruitment Status : Completed
First Posted : January 12, 2017
Last Update Posted : January 12, 2017
Sponsor:
Collaborator:
Simbec Research
Information provided by (Responsible Party):
Diurnal Limited

Brief Summary:
This was an open label, randomized, single dose, three period crossover pharmacokinetic study of Chronocort® in 30 healthy male volunteers. The study was conducted in smaller sub groups (Group 1, n=18 and Group 2, n=12).

Condition or disease Intervention/treatment Phase
Congenital Adrenal Hyperplasia Adrenal Insufficiency Drug: Hydrocortisone Drug: Chronocort Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Randomised, Single Dose, 3-period Crossover Study in Healthy Volunteers to: a) Compare the Pharmacokinetics of Chronocort® Formulations Versus Immediate Release Hydrocortisone, and (b) Determine the Dose Proportionality of Chronocort® Formulations
Study Start Date : March 2010
Actual Primary Completion Date : April 2010
Actual Study Completion Date : April 2010


Arm Intervention/treatment
Experimental: Group 1

Volunteers in group 1 received the following interventions:

Chronocort® 30 mg given at night (~ 23:00h) as a combination of one 10mg capsule and one 20mg capsule (n=18).

Chronocort® 30mg given as one 20mg capsule at night (~ 23:00h) and as one 10mg capsule in the morning (~ 7:00h) following the initial night-time dose (n=18).

Hydrocortisone 30mg given at night (~ 23:00h) given as three 10mg tablets (n=18).

Each administration of IMP was separated by a washout period of at least 7 days.

Drug: Hydrocortisone
Generic hydrocortisone

Drug: Chronocort
Modified formulation of hydrocortisone

Experimental: Group 2

Volunteers in group 2 received the following interventions:

Chronocort® 5mg given at night (~ 23:00h) as one 5mg capsule (n=12).

Chronocort® 10mg given at night (~ 23:00h) as one 10mg capsule (n=12).

Chronocort® 20mg given at night (~ 23:00h) as one 20mg capsule (n=12).

Each administration of IMP was separated by a washout period of at least 7 days.

Drug: Chronocort
Modified formulation of hydrocortisone




Primary Outcome Measures :
  1. Derived pharmacokinetic parameter: Tmax [ Time Frame: 24 hours ]
    Tmax measures the time at which Cmax - maximum serum concentration - is observed

  2. Derived pharmacokinetic parameter: Tlag [ Time Frame: 24 hours ]
    Tlag measures the delay between dosing and being able to observe the drug/metabolite within the sampling area (e.g., blood serum)

  3. Derived pharmacokinetic parameter: Cmax [ Time Frame: 24 hours ]
    Cmax measures the time taken for the drug/metabolite to reach maximum serum concentration

  4. Derived pharmacokinetic parameter: AUC(0 - t) (Area under the curve) [ Time Frame: 24 hours ]
    Area under the serum concentration versus time curve from time

  5. Derived pharmacokinetic parameter: AUC(0-∞)(Area under the curve) [ Time Frame: 24 hours ]
    Area under the serum concentration versus time curve from time = 0h extrapolated to infinity

  6. Derived pharmacokinetic parameter: CL [ Time Frame: 24 hours ]
    Time to drug clearance

  7. Derived pharmacokinetic parameter: T1/2 [ Time Frame: 24 hours ]
    Time required to reach 1/2 Cmax



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male volunteers between 18 and 60 years of age, inclusive (at screening).
  • Subjects with a Body Mass Index (BMI) of 21-28. Body Mass Index = Body weight (kg) / (Height (m))2.
  • Subjects with no clinically significant abnormal serum biochemistry, haematology and urine examination values within 14 days of the start of the study. The parameters measured included those shown in Appendix 3 of the Study Protocol.
  • Subjects with a negative urinary drugs of abuse screen (including alcohol), determined within 14 days of the start of the study.
  • Subjects with negative HIV and Hepatitis B and C results.
  • Subjects with no clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined within 14 days of the start of the study.
  • Subjects with no clinically-significant deviation outside the normal ranges for blood pressure and pulse measurements.
  • Subjects and sexual partners must have used effective contraception methods during the trial and for 3 months after the last dose, for example:

    • Oral contraceptive + condom
    • Intra-uterine device (IUD) + condom
    • Diaphragm with spermacide + condom
  • Subjects must have been available to complete the study.
  • Subjects must have satisfied a medical examiner about their fitness to participate in the study.
  • Subjects must have provided written informed consent to participate in the study.

Exclusion Criteria:

  • A clinically significant history of gastrointestinal disorder likely to influence drug absorption.
  • Receipt of regular medication within 14 days of the first study day (including high dose vitamins, dietary supplements or herbal remedies).
  • Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.
  • A clinically significant history of previous allergy / sensitivity to Hydrocortisone.
  • A clinically significant history of drug or alcohol abuse.
  • Inability to communicate well with the Investigator (i.e., language problem, poor mental development or impaired cerebral function).
  • Participation in a New Chemical Entity clinical study within the previous 16 weeks or a marketed drug clinical study within the previous 12 weeks.
  • Subjects who had consumed more than 2 units of alcohol per day within seven (7) days prior to the first dose or had consumed any alcohol within the 48 hour period prior to the first dose.
  • Donation of 450ml or more blood within the previous 12 weeks.
  • Subjects who worked shifts (i.e. regularly alternated between days, afternoons and nights).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03019614


Sponsors and Collaborators
Diurnal Limited
Simbec Research
Investigators
Layout table for investigator information
Principal Investigator: Salvatore Febbraro Simbec Research

Layout table for additonal information
Responsible Party: Diurnal Limited
ClinicalTrials.gov Identifier: NCT03019614     History of Changes
Other Study ID Numbers: DIUR-001
First Posted: January 12, 2017    Key Record Dates
Last Update Posted: January 12, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Adrenal Hyperplasia, Congenital
Adrenogenital Syndrome
Adrenal Insufficiency
Hyperplasia
Pathologic Processes
Adrenal Gland Diseases
Endocrine System Diseases
Disorders of Sex Development
Urogenital Abnormalities
Congenital Abnormalities
Genetic Diseases, Inborn
Steroid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Metabolic Diseases
Gonadal Disorders
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Anti-Inflammatory Agents